Stock Fundamentals

Company Information

Company Name
NewAmsterdam Pharma Company N.V. Ordinary Shares
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: NL00150012L7
CIK: 0001936258
Currency: USD
Full Time Employees: 100
Phone: 31 35 206 2971
Fiscal Year End: December
IPO Date: Nov 23, 2022
Description:

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Address:

Gooimeer 2-35, Naarden, Netherlands, 1411 DC

Directors & Officers

Name Title Year Born
Dr. Michael Harvey Davidson FACC, Facp., M.D. CEO, President & Executive Director 1956
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. Founder, Chief Scientific Officer, Member of Executive Board & Director 1954
Mr. Mayur Amrat Somaiya Chief Financial Officer 1974
Mr. Douglas F. Kling Chief Operating Officer 1973
Ms. Louise Kooij Chief Accounting Officer 1976
Mr. Matthew Philippe Executive VP & Head of Investor Relations NA
Mr. Michael F. Marino Esq. Chief Legal Officer & Corporate Secretary 1976
Mr. Chris Deluzio Executive Vice President of Sales Enterprise Operations NA
Ms. Maryellen McQuade Chief People Officer NA
Ms. Juliette Audet M.B.A., M.Sc. Chief Strategy & Business Officer 1987

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 11, 2026 Louis G Lange N/A Sale 44.62K $30.42 $1.36M
Mar 09, 2026 Johannes Jacob Piete Kastelein N/A Sale 101.41K $30.29 $3.07M
Mar 06, 2026 Johannes Jacob Piete Kastelein N/A Sale 94.12K $30.32 $2.85M
Mar 06, 2026 Louis G Lange N/A Sale 28.19K $29.41 $828.95K
Mar 05, 2026 Johannes Jacob Piete Kastelein N/A Sale 104.47K $30.30 $3.17M
Mar 02, 2026 Michael H Davidson N/A Sale 443.71K $33.25 $14.75M
Feb 26, 2026 Michael H Davidson N/A Sale 183.33K $33.71 $6.18M
Feb 25, 2026 Michael H Davidson N/A Sale 58.25K $35.30 $2.06M
Feb 24, 2026 Michael H Davidson N/A Sale 64.71K $36.15 $2.34M
Feb 20, 2026 Johannes Jacob Piete Kastelein N/A Sale 45.48K $35.31 $1.61M
Jan 28, 2026 Louise Frederika Kooij N/A Sale 32.61K $31.80 $1.04M
Jan 27, 2026 Louise Frederika Kooij N/A Sale 39.82K $32.62 $1.30M
Jan 26, 2026 Louise Frederika Kooij N/A Sale 34.40K $32.78 $1.13M
Jan 23, 2026 Louise Frederika Kooij N/A Sale 38.17K $33.75 $1.29M
Jan 05, 2026 Johannes Jacob Piete Kastelein N/A Sale 6.00K $33.25 $199.50K
Jan 05, 2026 Louise Frederika Kooij N/A Sale 2.65K $33.25 $88.01K
Dec 26, 2025 Louise Frederika Kooij N/A Sale 43.87K $35.30 $1.55M
Dec 24, 2025 Louise Frederika Kooij N/A Sale 26.01K $35.68 $928.07K
Dec 23, 2025 Louise Frederika Kooij N/A Sale 75.12K $36.21 $2.72M
Sep 15, 2025 James N Topper N/A Purchase 660.00 $23.70 $15.64K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Frazier Life Sciences Management, L.P. 16.94M Mar 31, 2026 14.49% $13.96 0.00%
Capital World Investors 11.11M Mar 31, 2026 9.50% $0.05 11.27%
RA Capital Management, LLC 9.55M Mar 31, 2026 8.17% $3.24 0.00%
FCPM III SERVICES BV 9.20M Mar 31, 2026 7.87% $40.77 0.00%
FMR Inc 8.77M Mar 31, 2026 7.50% $0.01 36.69%
Bain Capital Life Sciences Investors, LLC 7.31M Mar 31, 2026 6.25% $21.09 0.00%
Wellington Management Company LLP 5.12M Mar 31, 2026 4.38% $0.03 1.64%
Deerfield Management Co 4.26M Mar 31, 2026 3.65% $1.61 2.40%
Viking Global Investors LP 4.20M Mar 31, 2026 3.60% $0.38 0.00%
Duquesne Family Office LLC 3.07M Mar 31, 2026 2.63% $2.91 0.00%
Polar Capital Holdings PLC 2.83M Mar 31, 2026 2.42% $0.32 2.00%
Jennison Associates LLC 2.75M Mar 31, 2026 2.35% $0.06 -21.17%
Medicxi Ventures Management (Jersey) Ltd 2.67M Mar 31, 2026 2.29% $8.72 -6.81%
HHG PLC 2.26M Mar 31, 2026 1.93% $0.03 -3.53%
Westfield Capital Management Company, L.P. 2.20M Mar 31, 2026 1.88% $0.30 0.00%
Maverick Capital Ltd 2.19M Mar 31, 2026 1.87% $0.81 15.42%
The Goldman Sachs Group Inc 1.95M Mar 31, 2026 1.66% $0.01 12.79%
Capital Research & Mgmt Co - Division 3 1.44M Mar 31, 2026 1.23% $0.01 -30.13%
AllianceBernstein L.P. 1.20M Mar 31, 2026 1.03% $0.01 -7.81%
Adage Capital Partners Gp LLC 1.11M Mar 31, 2026 0.95% $0.05 -21.33%

Shares Statistics

Shares Outstanding: 116.90M
Shares Float: 80.70M
% Insiders: 91.40%
% Institutions: 10,621.90%
Short % Float: 8.14%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 American Funds SMALLCAP World A 8.40M 7.18% ▼ 2.33% Mar 31, 2026
2 Vanguard Health Care Inv 3.95M 3.38% ▲ 7.64% Mar 31, 2026
3 Capital Group Global Equity Canada F 2.52M 2.16% ▲ 0.00% Mar 31, 2026
4 Strategic Advisers Fidelity US TtlStk 2.00M 1.71% ▲ 12.43% Apr 30, 2026
5 Polar Capital Biotech S Inc 1.72M 1.47% ▼ 35.67% Apr 30, 2026
6 Fidelity Contrafund 1.58M 1.36% ▲ 24.82% Apr 30, 2026
7 American Funds New Economy A 957.48K 0.82% ▲ 42.67% Mar 31, 2026
8 Capital Group New Economy Comp 957.48K 0.82% ▲ 42.67% Mar 31, 2026
9 Fidelity Select Health Care 670.00K 0.57% ▲ 0.00% Apr 30, 2026
10 Candriam Eqs L Biotech C USD Cap 634.10K 0.54% ▼ 7.34% Nov 30, 2025

Valuation Metrics

Enterprise Value: $2.92B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $3.55B
EBITDA: $-214.95M
Book Value: $5.70
Earnings/Share: $-1.78
Profit Margin: 0.00%
Operating Margin: -1,921.71%
ROA (TTM): -17.34%
ROE (TTM): -29.49%
Revenue (TTM): $22.57M
Revenue/Share (TTM): $0.19
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 2.10%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 7.88x 0.00x 0.11x N/A 0.00x
2024-12-31 8.08x 0.00x 0.12x N/A 0.00x
2023-12-31 6.95x 0.00x 0.17x -26.91x 0.00x
2022-12-31 13.26x 0.00x 0.10x -12.39x 0.00x
2021-12-31 5.96x 0.00x 0.17x -85.10x 0.00x
2020-12-31 7.90x 0.09x 0.09x -19.28x -1.76x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NAMS.US!